Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2014

Open Access 01-12-2014 | Meeting abstract

The opportunity and imperative for point-of-care diagnostics in systemic lupus erythematosus

Author: Marvin J Fritzler

Published in: Arthritis Research & Therapy | Special Issue 1/2014

Login to get access

Excerpt

The development of point-of-care diagnostics (POCD) is prompted by the global burden of diseases attended by high morbidity and mortality when the diagnosis is delayed. POCD are designed to bring diagnostic tests immediately accessible to the site of patient care. In general terms, these devices are simple to use, economical, have high specificity and have a short turnaround time, enabling rapid clinical decisions. Contemporary POCD devices target blood glucose, coagulation, cardiac markers, infectious diseases, pregnancy and cholesterol testing. Systemic lupus erythematosus (SLE) is a suitable target for POCD because it can present with a variety of rapid-onset and life-threatening features, and is characterized by a number of well-defined disease-specific biomarkers. Clinical scenarios where POCD would benefit the management of SLE include CNS lupus (psychosis, encephalitis, stroke, seizures), transverse myelitis, acute renal failure, pulmonary hemorrhage and pneumonitis, cytopenias (thrombocytopenia, anemia, neutropenia, leukopenia), catastrophic antiphospholipid syndrome, cardiac tamponade and infarction, fetal heart block, mesenteric vasculitis and pancreatitis. …
Metadata
Title
The opportunity and imperative for point-of-care diagnostics in systemic lupus erythematosus
Author
Marvin J Fritzler
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4647

Other articles of this Special Issue 1/2014

Arthritis Research & Therapy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine